Literature DB >> 20424892

Novel 1-alkyl-tryptophan derivatives downregulate IDO1 and IDO2 mRNA expression induced by interferon-gamma in dendritic cells.

Ting Sun1, Xiang-Hua Chen, Zheng-De Tang, Jiong Cai, Xiao-Yan Wang, Shih-Chen Wang, Zhao-Long Li.   

Abstract

Indoleamine 2,3-dioxygenase (IDO) is an enzyme that suppresses adaptive T-cell immunity by catabolizing tryptophan from the cellular microenvironment. Inhibition of IDO pathway might enhance the efficacy of immunotherapeutic strategies for cancer. We synthesized 1-alkyl-tryptophan targeted IDO inhibitors and compared their effects on IDO expression and activity in dendritic cells (DCs) with the common IDO inhibitor 1-methyl-DL-tryptophan (1-MT). The IDO gene expression was examined by RT-PCR and realtime PCR. The toxicity of these analogs on the proliferation of DCs was detected by MTT assay. All of these analogs inhibited IDO expression and activity induced by IFN-gamma and showed no cytotoxicity to DCs at 100 microM. 1-MT intensively suppressed IDO1 expression and activity in DCs, and 1-propyl-tryptophan (1-PT) and 1-isopropyl-tryptophan (1-isoPT) moderately inhibited them. 1-Butyl-tryptophan (1-BT) and 1-ethyl-tryptophan (1-ET) mainly inhibited IDO2 expression. Our results suggest that those analogs differed in their inhibitory activity on IDO expression may give us a clue for developing active IDO inhibitors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20424892     DOI: 10.1007/s11010-010-0465-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  23 in total

1.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

Authors:  Alexander J Muller; James B DuHadaway; P Scott Donover; Erika Sutanto-Ward; George C Prendergast
Journal:  Nat Med       Date:  2005-02-13       Impact factor: 53.440

2.  Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells.

Authors:  Francesca Fallarino; Carmine Vacca; Ciriana Orabona; Maria L Belladonna; Roberta Bianchi; Brendan Marshall; Derin B Keskin; Andrew L Mellor; Maria C Fioretti; Ursula Grohmann; Paolo Puccetti
Journal:  Int Immunol       Date:  2002-01       Impact factor: 4.823

3.  Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.

Authors:  Paul Gaspari; Tinku Banerjee; William P Malachowski; Alexander J Muller; George C Prendergast; James DuHadaway; Shauna Bennett; Ashley M Donovan
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

4.  Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation.

Authors:  P Hwu; M X Du; R Lapointe; M Do; M W Taylor; H A Young
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

5.  A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation.

Authors:  Deborah Braun; Randy S Longman; Matthew L Albert
Journal:  Blood       Date:  2005-06-09       Impact factor: 22.113

6.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

7.  T cell apoptosis by kynurenines.

Authors:  Francesca Fallarino; Ursula Grohmann; Carmine Vacca; Ciriana Orabona; Antonio Spreca; Maria C Fioretti; Paolo Puccetti
Journal:  Adv Exp Med Biol       Date:  2003       Impact factor: 2.622

8.  IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.

Authors:  Stefan Löb; Alfred Königsrainer; Derek Zieker; Björn L D M Brücher; Hans-Georg Rammensee; Gerhard Opelz; Peter Terness
Journal:  Cancer Immunol Immunother       Date:  2008-04-17       Impact factor: 6.968

9.  Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes.

Authors:  S R Thomas; D Mohr; R Stocker
Journal:  J Biol Chem       Date:  1994-05-20       Impact factor: 5.157

10.  Intracellular uptake and inhibitory activity of aromatic fluorinated amino acids in human breast cancer cells.

Authors:  Christoph Giese; Sandra Lepthien; Linda Metzner; Matthias Brandsch; Nediljko Budisa; Hauke Lilie
Journal:  ChemMedChem       Date:  2008-09       Impact factor: 3.466

View more
  10 in total

1.  1-butyltryptophan inhibits cell proliferation, migration, and invasion through the Akt pathway in human gastric cancer cells.

Authors:  Ting Sun; Hua Tian; YangXun Xin
Journal:  Tumour Biol       Date:  2014-11-30

2.  IDO1 depletion induces an anti-inflammatory response in macrophages in mice with chronic viral myocarditis.

Authors:  Gongliang Guo; Liqun Sun; Lili Yang; Haiming Xu
Journal:  Cell Cycle       Date:  2019-08-15       Impact factor: 4.534

Review 3.  IDO and TDO as a potential therapeutic target in different types of depression.

Authors:  Yanjie Qin; Nanxi Wang; Xinlin Zhang; Xuemei Han; Xuejia Zhai; Yongning Lu
Journal:  Metab Brain Dis       Date:  2018-07-16       Impact factor: 3.584

Review 4.  IDO2 in Immunomodulation and Autoimmune Disease.

Authors:  George C Prendergast; Richard Metz; Alexander J Muller; Lauren M F Merlo; Laura Mandik-Nayak
Journal:  Front Immunol       Date:  2014-11-20       Impact factor: 7.561

Review 5.  Tryptophan-degrading enzymes in tumoral immune resistance.

Authors:  Nicolas van Baren; Benoît J Van den Eynde
Journal:  Front Immunol       Date:  2015-02-03       Impact factor: 7.561

6.  Gene silencing of indoleamine 2,3-dioxygenase 2 in melanoma cells induces apoptosis through the suppression of NAD+ and inhibits in vivo tumor growth.

Authors:  Yanling Liu; Yujuan Zhang; Xiufen Zheng; Xusheng Zhang; Hongmei Wang; Qin Li; Keng Yuan; Nanjing Zhou; Yanrong Yu; Na Song; Jiamin Fu; Weiping Min
Journal:  Oncotarget       Date:  2016-05-31

Review 7.  IDO2: A Pathogenic Mediator of Inflammatory Autoimmunity.

Authors:  Lauren M F Merlo; Laura Mandik-Nayak
Journal:  Clin Med Insights Pathol       Date:  2016-11-21

Review 8.  Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges.

Authors:  Xuerun Peng; Zhipeng Zhao; Liwen Liu; Lan Bai; Rongsheng Tong; Hao Yang; Lei Zhong
Journal:  Drug Des Devel Ther       Date:  2022-08-08       Impact factor: 4.319

9.  Effects of various phytochemicals on indoleamine 2,3-dioxygenase 1 activity: galanal is a novel, competitive inhibitor of the enzyme.

Authors:  Rie Yamamoto; Yasuko Yamamoto; Shinjiro Imai; Ryuta Fukutomi; Yoshio Ozawa; Masako Abe; Yushi Matuo; Kuniaki Saito
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

Review 10.  The Kynurenine Pathway As a Novel Link between Allergy and the Gut Microbiome.

Authors:  Aaron P Van der Leek; Yarden Yanishevsky; Anita L Kozyrskyj
Journal:  Front Immunol       Date:  2017-11-06       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.